J W Murrough1, L Soleimani1, K E DeWilde1, K A Collins1, K A Lapidus2, B M Iacoviello1, M Lener1, M Kautz1, J Kim3, J B Stern4, R B Price5, A M Perez6, J W Brallier6, G J Rodriguez7, W K Goodman7, D V Iosifescu1, D S Charney1. 1. Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA. 2. Departments of Psychiatry and Neurobiology,Stony Brook University,Stony Brook,NY,USA. 3. Deparment of Psychology,UCLA,Los Angeles,CA,USA. 4. Department of Psychology,Drexel University,Philadelphia,PA,USA. 5. Department of Psychiatry,University of Pittsburgh School of Medicine,Pittsburgh,PA,USA. 6. Department of Anesthesiology,Icahn School of Medicine at Mount Sinai,New York,NY,USA. 7. Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA.
Abstract
BACKGROUND: Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI). We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression. METHOD: We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24). Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care. SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome. Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point. RESULTS: The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period. BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047). MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05). The treatment effect was no longer significant at the end of the 7-day assessment period. CONCLUSIONS: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior. Larger, well-powered studies are warranted.
RCT Entities:
BACKGROUND: Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI). We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression. METHOD: We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24). Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care. SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome. Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point. RESULTS: The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period. BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047). MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05). The treatment effect was no longer significant at the end of the 7-day assessment period. CONCLUSIONS: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior. Larger, well-powered studies are warranted.
Authors: Elizabeth D Ballard; Kathleen Wills; Níall Lally; Erica M Richards; David A Luckenbaugh; Tessa Walls; Rezvan Ameli; Mark J Niciu; Nancy E Brutsche; Lawrence Park; Carlos A Zarate Journal: J Affect Disord Date: 2017-04-25 Impact factor: 4.839
Authors: Nolan R Williams; Boris D Heifets; Brandon S Bentzley; Christine Blasey; Keith D Sudheimer; Jessica Hawkins; David M Lyons; Alan F Schatzberg Journal: Mol Psychiatry Date: 2019-08-29 Impact factor: 15.992
Authors: Elizabeth D Ballard; Julia S Yarrington; Cristan A Farmer; Erica Richards; Rodrigo Machado-Vieira; Bashkim Kadriu; Mark J Niciu; Peixiong Yuan; Lawrence Park; Carlos A Zarate Journal: J Affect Disord Date: 2018-07-30 Impact factor: 4.839
Authors: Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468
Authors: Michael F Grunebaum; Hanga C Galfalvy; Tse-Hwei Choo; John G Keilp; Vivek K Moitra; Michelle S Parris; Julia E Marver; Ainsley K Burke; Matthew S Milak; M Elizabeth Sublette; Maria A Oquendo; J John Mann Journal: Am J Psychiatry Date: 2017-12-05 Impact factor: 18.112
Authors: Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán Journal: Behav Brain Res Date: 2020-02-01 Impact factor: 3.332